Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib DDI with Oral Contraceptives in Solid Tumors
NCT02292732Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Feb 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of trametinib in solid tumor, sponsored by GSK. Primary endpoint: Composite of steady state PK parameters of Norethindrone and Ethinyl Estradiol at Day 12. Planned start Feb 2016; status: withdrawn.
02
Drugs
trametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02292732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292732.